Financial Spine Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 byJosh SandbergJuly 29, 2026
Spine Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice byTim AllenJuly 22, 2026
Spine Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform byTim AllenJune 10, 2026
Financial Aclarion Publishes 2026 Shareholder Letter from the Chairman byJosh SandbergFebruary 5, 2026
Spine Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation byJosh SandbergFebruary 3, 2026
Spine Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data byTim AllenJanuary 7, 2026
Spine Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS) byTim AllenDecember 4, 2025
Spine Top Stories Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion byJosh SandbergNovember 5, 2025
